[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289327":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":55,"collaborators":17,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":17,"enrollmentInfo":68,"targetDuration":17,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":36,"whyStopped":17,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Guangdong Association of Clinical Trials","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"local consolidative treatment","Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.",[12],"Other: local consolidative treatment",[14],{"type":6,"name":9,"description":15,"armGroupLabels":16,"otherNames":17},"local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy",[9],null,[19],{"name":20,"affiliation":21,"role":22},"Zhen Wang, PhD,MD","Guangdong General Hospital&Guangdong Academy of Medical Sciences","PRINCIPAL_INVESTIGATOR",[24,30],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"ZHEN WANG, PhD,MD","CONTACT","+8683827812","50811","hunterol@163.com",{"name":31,"role":26,"phone":27,"phoneExt":28,"email":32},"Hui-fen Huang","huifen8839@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Guangdong General Hospital","RECRUITING","Guangzhou","Guagndong","510080","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.25,23.11667,{"lat":46,"lon":45},[49,52],{"name":50,"role":26,"phone":51,"phoneExt":28,"email":29},"ZHEN WANG, PhD","862083827812",{"name":53,"role":26,"phone":51,"phoneExt":54,"email":32},"Huifen Huang","50810",{"type":22,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Yi-Long Wu","Dr.","100289327","local-therapy-in-advanced-nsclc-with-non-progressive-disease-pd-after-first-line-therapy-100289327",false,"NCT03046316","Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy","Local Consolidative Therapy (LCT) in Patients With Advanced Stage Non-small Cell Lung Cancer Who do Not Progress After Front Line Systemic Therapy","LOCAL","Inclusion Criteria:\n\n* Male or female, age \\>= 18 years, with life expectancy of at least 12 weeks.\n* Patients with histologically documented metastatic (stage IV) non-small cell lung cancer.\n* Subjected to driving genes examination including EGFR, ALK and ROS1.\n* Achieve complete response (CR)\u002Fpartial response (PR)\u002Fstable disease (SD) after front line systemic treatment (chemotherapy, targeted therapy or immunological checkpoint inhibitors).\n* Total metastatic lesions is limited to five.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \\\u003C= 2.\n* Patients must have measurable disease according to the RECIST (version 1.1) criteria.\n* Adequate organ function as defined by the following criteria:\n\n  * Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C= 2.5 upper limit of normal (ULN) in the absence of liver metastases or up to 5 ULN in case of liver metastases. Total bilirubin \\\u003C= 1.5 ULN.\n  * Bone marrow function: Granulocyte count \\>= 1,500\u002Fmm3 and platelet count ≥100,000\u002Fmm3 and hemoglobin \\>= 80g\u002Fdl.\n  * Renal function: serum creatinine \\\u003C= 1.5 ULN or creatinine clearance \\>= 60 ml\u002Fmin. (based on modified Cockcroft-Gault formula).\n  * Adequate coagulating function.\n* For all females of childbearing potential a negative serum\u002Furine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Males must agree to use effective contraception during the study period and for at least 12 weeks after completion of the study treatment.\n* Written (signed) informed Consent to participate in the study.\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Stage I-III a NSCLC completing radical treatment , then undergoing systemic anti-cancer treatment after recurrence.\n* Patients with PFS no more than 3 months. to first line theray.\n* Patients with history of any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).\n* Prior palliative surgery or other local therapy specifically directed against advanced lung cancer.\n* Contraindication for localized treatment including surgery, radiotherapy or interventional therapy judged by physicians.\n* Patients with any unstable systemic disease (including active infections, significant cardiovascular disease, any significant hepatic, renal or metabolic disease).\n* Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids.\n* Nursing or lactating women.\n* Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.\n* Patients who has mental disorder or other disease that contribute to no compliance.\n* Unwilling to write informed consent to participate in the study.\n* Patients who is unwilling to accept the follow-up.","ALL","18 Years",{"count":69,"type":70},60,"ESTIMATED","INTERVENTIONAL",[73],"NA","This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III\u002FIV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).",[76],"Lung Neoplasms",[78,79],"Therapeutics","local therapy","2020-07-21",{"date":82,"type":83},"2020-07-23","ACTUAL",{"date":85,"type":83},"2020-06-01",{"date":87,"type":70},"2026-07-01",{"name":5,"class":6},1]